Key result
Early aggressive immunosuppression linked to LVEF recovery to ~50% in two lupus myocarditis cases.
Why the study?
Does early aggressive immunosuppression combined with heart failure therapy improve LVEF and resolve symptoms in young women with lupus myocarditis?
Case Report (n=2)
Does early aggressive immunosuppression combined with heart failure therapy improve LVEF and resolve symptoms in young women with lupus myocarditis?
Answers are grounded in this paper and cite their sources.
Early aggressive immunosuppression combined with guideline-directed medical therapy can lead to rapid and significant LVEF recovery in patients with acute lupus myocarditis.
We present two cases (females aged 23 and 36 years) with newly diagnosed systemic lupus erythematosus who developed lupus myocarditis concurrent with lupus nephritis. Both exhibited acute decompensated heart failure with dyspnea, edema, and cardiomegaly. Common key findings included strongly positive ANA blot, nephrotic-range proteinuria, acute kidney injury, and markedly elevated NT-proBNP (>35,000 pg/mL). Transthoracic echocardiography confirmed biventricular dysfunction (left ventricular ejection fraction [LVEF]: 20%-35% initially), moderate-to-severe tricuspid regurgitation, moderate-to-severe pulmonary arterial hypertension, and mild pericardial effusions. Both received high-dose pulse dexamethasone (40-60 mg IV), hydroxychloroquine (HCQ), diuretics, beta-blockers, SGLT2 inhibitors, and HCQ. The fulminant case additionally underwent plasma exchange. Both the patients, over the next few weeks, received cyclophosphamide therapy and achieved LVEF recovery to 50%-55% within 1-2 months, with improved renal function and resolution of heart failure symptoms. These cases underscore the reversibility of lupus myocarditis with early aggressive immunosuppression.
No takes yet. Share an insight, caveat, or question.
Gokhale et al. (2026) conducted a case report in Systemic lupus erythematosus with lupus myocarditis and lupus nephritis (n=2). Early aggressive immunosuppression (dexamethasone, cyclophosphamide, hydroxychloroquine) and heart failure therapy was evaluated on LVEF recovery and resolution of heart failure symptoms. Early aggressive immunosuppression led to LVEF recovery from 20%-35% to 50%-55% within 1-2 months and resolution of heart failure symptoms in two women with lupus myocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: